ESMO

Krazati Associated With Superior Outcomes Than Docetaxel in KRAS G12C+ NSCLC

September 24th 2024, 9:00pm

Article

Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.

Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC

September 24th 2024, 1:00pm

Article

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.

Nubeqa Plus ADT Outperformed ADT Alone in Treating Prostate Cancer

September 23rd 2024, 9:00pm

Article

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer.

Enhertu Maintains QOL, Slows Pain in HR+/HER2 Metastatic Breast Cancer

September 23rd 2024, 1:00pm

Article

Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, without affecting overall quality of life.

Challenges to Consider While Receiving Fotivda for Kidney Cancer

September 21st 2024, 2:00pm

Video

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma

September 20th 2024, 7:00pm

Article

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

Survival Rate Increased With Yervoy-Opdivo Combo in Kidney Cancer

September 20th 2024, 1:00pm

Article

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.

Study Confirms Lenvima’s Benefits in Thyroid Cancer

September 19th 2024, 9:00pm

Article

First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.

Braftovi Regimen Is Promising in Metastatic Colorectal Cancer

September 19th 2024, 1:00pm

Article

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of Braftovi, Erbitux and chemotherapy showed promising antitumor activity.

Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer

September 18th 2024, 1:00pm

Article

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.